The slow and steady release of the PI3‐Kδ/HDAC6 dual inhibitor from HSB‐510 led to 2–3 times higher in vitro IC50 values as compared to free PI3‐Kδ/HDAC6 dual inhibitor evaluated in breast cancer cell lines. Here, HDAC6 is linked to breast cancer.